Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
- Details
- Category: Bayer
Bayer has entered into an exclusive global collaboration with Loxo Oncology, Inc., a biopharmaceutical company based in Stamford, Connecticut, US, (NASDAQ: LOXO) for the development and commercialization of larotrectinib (LOXO-101) and LOXO-195. Both compounds are being investigated in global studies for the treatment of patients with cancers harboring tropomyosin receptor kinase (TRK) gene fusions,
Pfizer receives FDA approval for SUTENT® (sunitinib malate) as first and only adjuvant treatment for adult patients at high risk of recurrent renal cell carcinoma
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy (surgical removal of the cancerous kidney).
Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma
- Details
- Category: AstraZeneca
AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
New Novartis Entresto® real world evidence data shows beneficial impact on quality of life in people living with heart failure
- Details
- Category: Novartis
Novartis has announced new results from a real-world database study of patients in Germany prescribed Entresto® (sacubitril/valsartan) for heart failure with reduced ejection fraction (HFrEF). The findings further substantiate the beneficial effect of Entresto on heart failure symptoms and patients' quality of life observed in the PARADIGM-HF study and in other real-world cohorts.
BMS-Pfizer Alliance to unveil real-world data analyses - cost, safety and comparative effectiveness findings associated with oral anticoagulants in non-valvular atrial fibrillation
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) plan to release real-world data (RWD) analyses of outcomes associated with direct oral anticoagulants (DOAC) among non-valvular atrial fibrillation (NVAF) patients using the U.S. Medicare database - the nation's largest insurer handling more than one billion total claims per year(1)
Boehringer Ingelheim and MiNA Therapeutics to develop novel treatment approaches for fibrotic liver diseases
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and MiNA Therapeutics ("MiNA"), a pioneer in RNA activation therapeutics, have signed a collaboration and licensing agreement focused on the development of novel compounds to treat fibrotic liver diseases such as NASH, based on MiNA's small activating RNA ("saRNA") therapeutics platform.
Sanofi, Principia agree to develop multiple sclerosis drug candidate
- Details
- Category: Sanofi
Sanofi will develop Principia Biopharma Inc.'s experimental oral treatment that shows promise in multiple sclerosis (MS) and, potentially, other central nervous system (CNS) diseases. Under the license agreement signed this week, Sanofi will develop Principia's Bruton's tyrosine kinase (BTK) inhibitor (PRN2246), which was designed to access the brain and spinal cord by crossing the blood-brain barrier and impact immune cell and brain cell signalling.
More Pharma News ...
- Spark Therapeutics and Pfizer amend license agreement for investigational SPK-9001 in hemophilia B
- Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®
- Amgen and Novartis announce expanded collaboration with Banner Alzheimer's Institute in pioneering prevention program
- New US study reveals key reasons why millions of people with obesity are not receiving adequate care
- FDA approves AstraZeneca's Calquence (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma
- Boehringer Ingelheim expands collaboration with Sarah Cannon Research Institute to investigate novel immuno-oncology combination therapy
- Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio